Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Issues Earnings Results

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) issued its quarterly earnings results on Tuesday. The company reported $0.88 earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $770.90 million during the quarter.

Recordati Industria Chimica E Farmaceutica Price Performance

RCDTF remained flat at $56.95 on Thursday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.64 and a quick ratio of 1.16. Recordati Industria Chimica E Farmaceutica has a fifty-two week low of $49.00 and a fifty-two week high of $65.44. The stock has a market capitalization of $11.75 billion, a price-to-earnings ratio of 16.90 and a beta of 0.26. The stock has a 50 day moving average price of $61.03 and a 200 day moving average price of $63.90.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on RCDTF. Barclays upgraded shares of Recordati Industria Chimica E Farmaceutica from a “strong sell” rating to a “hold” rating in a report on Thursday, February 12th. Kepler Capital Markets raised Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 3rd. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Recordati Industria Chimica E Farmaceutica currently has an average rating of “Buy”.

Recordati Industria Chimica E Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.